A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT05091541 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non-Hodgkin's Lymphoma

Interventions

DRUG: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection

Sponsor

Nanjing IASO Biotechnology Co., Ltd.